Immix Biopharma (NASDAQ:IMMX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $7.00 target price on the stock.

Immix Biopharma Stock Performance

Shares of IMMX opened at $1.99 on Monday. Immix Biopharma has a fifty-two week low of $1.26 and a fifty-two week high of $3.80. The company’s fifty day moving average is $2.14 and its 200 day moving average is $1.93. The stock has a market capitalization of $54.74 million, a PE ratio of -2.34 and a beta of 0.24.

Immix Biopharma (NASDAQ:IMMX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). As a group, research analysts forecast that Immix Biopharma will post -0.87 earnings per share for the current year.

Institutional Investors Weigh In On Immix Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMMX. SBI Securities Co. Ltd. purchased a new position in shares of Immix Biopharma in the 4th quarter worth approximately $38,000. FNY Investment Advisers LLC bought a new stake in Immix Biopharma in the fourth quarter worth $63,000. Finally, Geode Capital Management LLC lifted its position in Immix Biopharma by 5.6% in the third quarter. Geode Capital Management LLC now owns 150,082 shares of the company’s stock worth $224,000 after buying an additional 7,954 shares during the last quarter. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.